Seiwert, T. Y., Wildsmith, S., Fayette, J., Harrington, K., Gillison, M., Ahn, M., . . . Psyrri, A. (2024). Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma. Cancer Immunology, Immunotherapy, 73(4), . https://doi.org/10.1007/s00262-024-03643-3
Chicago-referens (17:e uppl.)Seiwert, Tanguy Y., et al. "Outcomes in Biomarker-selected Subgroups from the KESTREL Study of Durvalumab and Tremelimumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma." Cancer Immunology, Immunotherapy 73, no. 4 (2024). https://doi.org/10.1007/s00262-024-03643-3.
MLA-referens (9:e uppl.)Seiwert, Tanguy Y., et al. "Outcomes in Biomarker-selected Subgroups from the KESTREL Study of Durvalumab and Tremelimumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma." Cancer Immunology, Immunotherapy, vol. 73, no. 4, 2024, https://doi.org/10.1007/s00262-024-03643-3.
